Tdose Binding and Tocilizumab

Summary

The investigators aim to evaluate the non-inferiority of administering tocilizumab at a fixed dose versus a weight-based dose in patients with rheumatoid arthritis in remission or with low clinical activity, after 3 months of treatment, as part of a two-center randomized trial.

Timeline

Start

2026-06-01

Primary completion

2026-09-30

Completion

2026-12-31

Drugs

Indications